Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma|
Recent studies highlight comparable results with haploidentical SCT and cord blood SCT, thus providing alternate donor sources. Disease relapse and late effects continue to be major problems. Optimization of SCT techniques, post-transplant monitoring of minimal residual disease, and post-transplant maintenance, or pre-emptive therapy are emerging strategies to reduce the risk of relapse. [Curr Hematol Malig Rep] Abstract
Visit our reviews page to see a complete list of reviews in the cord blood research field.
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma|
Kite Pharma, Inc. announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab, in patients with refractory, aggressive non-Hodgkin lymphoma. [Kite Pharma, Inc.] Press Release
Blavatnik Biomedical Accelerator at Harvard University Announces License and Collaboration Agreement with Merck to Develop Novel Cancer Therapeutics
Harvard University has entered into an exclusive license and research collaboration agreement with Merck to further the development of small-molecule therapeutics for leukemia and other cancers. The novel compounds, developed in the laboratory of Harvard scientist Matthew Shair, Ph.D., offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription. [Harvard Office of Technology Development] Press Release
From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells. Watch now.